Kevin Christopher Zorn

Kevin Christopher Zorn

Auto-generated profile, based on publicly available information

Kevin Christopher Zorn

Division of Urology, Centre hospitalier de l’Université de Montréal, Montréal, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2022 in BJU International
Verified
Journal Article
Closed access
DEDean Elterman
Dean Elterman
NBNaeem Bhojani
Naeem Bhojani
CVChristopher Vannabouathong
Christopher Vannabouathong
BCBilal Chughtai
Bilal Chughtai
KZKevin C. Zorn
Kevin C. Zorn

2 March 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
DNDavid-Dan Nguyen
David-Dan Nguyen
VMVincent Misraï
Vincent Misraï
TBThorsten Bach
Thorsten Bach
NBNaeem Bhojani
Naeem Bhojani
JLJames E. Lingeman
James E. Lingeman
KZKevin C. Zorn
Kevin C. Zorn

4 April 2015 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
PHPierre-Alain Hueber
Pierre-Alain Hueber
MBMarc Nicolas Bienz
Marc Nicolas Bienz
RVRoger Valdivieso
Roger Valdivieso
HLHugo Lavigueur-Blouin
Hugo Lavigueur-Blouin
VMVincent Misrai
Vincent Misrai
KZKevin C. Zorn
Kevin C. Zorn
We evaluated photoselective vaporization of the prostate using the GreenLight™ XPS™ 180 W system for benign prostatic hyperplasia treatment in a large multi-institutional cohort at 2 years. We particularly examined safety, outcomes and the re-treatment rate in larger prostates, defined as a prostate volume of 80 cc or greater, to assess the potential of photoselective vaporization of the prostate as a size independent procedure. A total of 1,196 patients were treated at 6 international centers in Canada, the United States, France and England. All parameters were collected retrospectively, including complications, I-PSS, maximum urinary flow rate, post-void residual urine, prostate volume, prostate specific antigen and the endoscopic re-intervention rate. Subgroup stratified comparative analysis was performed according to preoperative prostate volume less than 80 vs 80 cc or greater on transrectal ultrasound. Median prostate size was 50 cc in 387 patients and 108 cc in 741 in the prostate volume groups less than 80 and 80 cc or greater, respectively. The rate of conversion to transurethral prostate resection was significantly higher in the 80 cc or greater group than in the less than 80 cc group (8.4% vs 0.6%, p <0.01). I-PSS, quality of life score, maximum urinary flow rate and post-void residual urine were significantly improved compared to baseline at 6, 12 and 24 months of followup without significant differences between the prostate size groups. The re-treatment rate at 2 years reported in 5 of 411 patients was associated with the delivery of decreased energy density (2.1 vs 4.4 kJ/cc) in the group without re-treatment. Photoselective vaporization of the prostate using the XPS 180 W system is safe and efficacious, providing durable improvement in functional outcomes at 2 years independent of prostate size when treated with sufficient energy.

22 February 2017 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MMMalek Meskawi
Malek Meskawi
PHPierre-Alain Hueber
Pierre-Alain Hueber
RVRoger Valdivieso
Roger Valdivieso
FBFranck Bruyere
Franck Bruyere
VMVincent Misrai
Vincent Misrai
KZKevin C. Zorn
Kevin C. Zorn

1 July 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KDKiran Devisetty
Kiran Devisetty
KZKevin C. Zorn
Kevin C. Zorn
MKMark H. Katz
Mark H. Katz
AJAshesh B. Jani
Ashesh B. Jani
SLStanley Liauw
Stanley Liauw

9 May 2017 in Canadian Urological Association Journal
Verified
Journal Article
Open access
PDF file
EREmad Sabri Rajih
Emad Sabri Rajih
CTCôme Tholomier
Côme Tholomier
BCBeatrice Cormier
Beatrice Cormier
VSVanessa Samouëlian
Vanessa Samouëlian
TWThomas Warkus
Thomas Warkus
KZKevin C. Zorn
Kevin C. Zorn
Introduction: The goal of the study is to evaluate and report on the third-generation da Vinci surgical (Si) system malfunctions.Methods: A total of 1228 robotic surgeries were performed between January 2012 and December 2015 at our academic centre. All cases were performed by using a single, dual console, four-arm, da Vinci Si robot system. The three specialties included urology, gynecology, and thoracic surgery. Studied outcomes included the robotic surgical error types, immediate consequences, and operative side effects. Error rate trend with time was also examined.Results: Overall robotic malfunctions were documented on the da Vinci Si systems event log in 4.97% (61/1228) of the cases. The most common error was related to pressure sensors in the robotic arms indicating out of limit output. This recoverable fault was noted in 2.04% (25/1228) of cases. Other errors included unrecoverable electronic communication-related in 1.06% (13/1228) of cases, failed encoder error in 0.57% (7/1228), illuminator-related in 0.33% (4/1228), faulty switch in 0.24% (3/1228), battery-related failures in 0.24% (3/1228), and software/hardware error in 0.08% (1/1228) of cases. Surgical delay was reported only in one patient. No conversion to either open or laparoscopic occurred secondary to robotic malfunctions. In 2015, the incidence of robotic error rose to 1.71% (21/1228) from 0.81% (10/1228) in 2014.Conclusions: Robotic malfunction is not infrequent in the current era of robotic surgery in various surgical subspecialties, but rarely consequential. Their seldom occurrence does not seem to affect patient safety or surgical outcome.